JP6282586B2 - 眼の炎症状態を治療するためのエステル - Google Patents

眼の炎症状態を治療するためのエステル Download PDF

Info

Publication number
JP6282586B2
JP6282586B2 JP2014518632A JP2014518632A JP6282586B2 JP 6282586 B2 JP6282586 B2 JP 6282586B2 JP 2014518632 A JP2014518632 A JP 2014518632A JP 2014518632 A JP2014518632 A JP 2014518632A JP 6282586 B2 JP6282586 B2 JP 6282586B2
Authority
JP
Japan
Prior art keywords
acid
eye
ester
inflammatory lipid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014518632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518261A (ja
Inventor
ガロワ−ベルノ・アナベル
モロック・ジュニア・フランク・エフ
デイビス・キャリー・エル
ロレンツ・キャシー・オズボーン
ヤング・ジェームズ・ケイ
カナバン・クリスティ・エル
ル・ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Vision Care Inc
Original Assignee
Johnson and Johnson Vision Care Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Vision Care Inc filed Critical Johnson and Johnson Vision Care Inc
Publication of JP2014518261A publication Critical patent/JP2014518261A/ja
Application granted granted Critical
Publication of JP6282586B2 publication Critical patent/JP6282586B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eyeglasses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014518632A 2011-06-30 2012-06-19 眼の炎症状態を治療するためのエステル Expired - Fee Related JP6282586B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161503158P 2011-06-30 2011-06-30
US61/503,158 2011-06-30
US13/495,049 2012-06-13
US13/495,049 US10383839B2 (en) 2011-06-30 2012-06-13 Esters for treatment of ocular inflammatory conditions
PCT/US2012/043078 WO2013003113A1 (en) 2011-06-30 2012-06-19 Esters for treatment of ocular inflammatory conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017195808A Division JP6675361B2 (ja) 2011-06-30 2017-10-06 眼の炎症状態を治療するためのエステル

Publications (2)

Publication Number Publication Date
JP2014518261A JP2014518261A (ja) 2014-07-28
JP6282586B2 true JP6282586B2 (ja) 2018-02-21

Family

ID=47391255

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014518632A Expired - Fee Related JP6282586B2 (ja) 2011-06-30 2012-06-19 眼の炎症状態を治療するためのエステル
JP2014518633A Active JP6352177B2 (ja) 2011-06-30 2012-06-19 眼の炎症状態を治療するためのエステル
JP2017195808A Expired - Fee Related JP6675361B2 (ja) 2011-06-30 2017-10-06 眼の炎症状態を治療するためのエステル
JP2019109332A Pending JP2019178150A (ja) 2011-06-30 2019-06-12 眼の炎症状態を治療するためのエステル

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014518633A Active JP6352177B2 (ja) 2011-06-30 2012-06-19 眼の炎症状態を治療するためのエステル
JP2017195808A Expired - Fee Related JP6675361B2 (ja) 2011-06-30 2017-10-06 眼の炎症状態を治療するためのエステル
JP2019109332A Pending JP2019178150A (ja) 2011-06-30 2019-06-12 眼の炎症状態を治療するためのエステル

Country Status (14)

Country Link
US (7) US8865685B2 (pt)
EP (3) EP3556346B1 (pt)
JP (4) JP6282586B2 (pt)
KR (4) KR102022838B1 (pt)
CN (5) CN108969471A (pt)
AR (2) AR086825A1 (pt)
AU (10) AU2012275760B2 (pt)
BR (2) BR112013034054A2 (pt)
CA (2) CA2840155C (pt)
ES (1) ES2743174T3 (pt)
PL (1) PL3556346T3 (pt)
RU (8) RU2640506C9 (pt)
TW (4) TWI633883B (pt)
WO (2) WO2013003113A1 (pt)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170006A2 (en) 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11020406B2 (en) 2015-09-03 2021-06-01 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41912A (fr) * 2015-04-07 2018-02-13 Hyalblue S R L Esters de glycosaminoglycane, procédés pour leur préparation et leur utilisation dans des formulations à usage ophtalmique
US10525012B2 (en) * 2015-08-11 2020-01-07 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN108096181A (zh) * 2018-02-05 2018-06-01 西安医学院 Dha、epa在制备治疗干眼症的口服药物的应用
NO345574B1 (en) 2018-06-19 2021-04-26 Epax Norway As Composition for treatment of dry eye disease and meibomianitis
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
CA3136137A1 (en) * 2019-04-04 2020-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
CN116018532A (zh) * 2020-08-10 2023-04-25 博士伦爱尔兰有限公司 包装溶液
US20220187620A1 (en) * 2020-12-15 2022-06-16 Coopervision International Limited Oleic acid-releasing contact lens
US12012238B2 (en) 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
WO2023049791A1 (en) * 2021-09-22 2023-03-30 The Trustees Of Columbia University In The City Of New York Delivery systems for bioactive lipids

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577446A (en) 1968-09-09 1971-05-04 American Home Prod Phosphatidylalkanolamine derivatives
US4330383A (en) 1978-07-18 1982-05-18 Polymer Technology Corporation Dimensionally stable oxygen permeable hard contact lens material and method of manufacture
US4495313A (en) 1981-04-30 1985-01-22 Mia Lens Production A/S Preparation of hydrogel for soft contact lens with water displaceable boric acid ester
JPS60110855A (ja) 1983-11-17 1985-06-17 Toshiba Corp 装飾部品の製造方法
JPS6123860A (ja) 1984-07-12 1986-02-01 Yamaha Motor Co Ltd 多気筒エンジンの給気装置
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
DE3704825A1 (de) 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5039459A (en) 1988-11-25 1991-08-13 Johnson & Johnson Vision Products, Inc. Method of forming shaped hydrogel articles including contact lenses
US4889664A (en) 1988-11-25 1989-12-26 Vistakon, Inc. Method of forming shaped hydrogel articles including contact lenses
US4915974A (en) 1989-02-17 1990-04-10 Nabisco Brands, Inc. Polyvinyl oleate as a fat replacement
SE9101642D0 (sv) 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
JPH06123860A (ja) 1992-10-09 1994-05-06 Tokyo Keikaku:Kk 酸素透過性ハードコンタクトレンズ
US5472703A (en) * 1993-03-02 1995-12-05 Johnson & Johnson Vision Products, Inc. Ophthalmic lens with anti-toxin agent
US5337888A (en) * 1993-09-01 1994-08-16 Morrison Robert J Contact lens case
US5460802A (en) * 1994-07-18 1995-10-24 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
US7468398B2 (en) 1994-09-06 2008-12-23 Ciba Vision Corporation Extended wear ophthalmic lens
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
DE19511322C2 (de) 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
TW585882B (en) 1995-04-04 2004-05-01 Novartis Ag A method of using a contact lens as an extended wear lens and a method of screening an ophthalmic lens for utility as an extended-wear lens
EP1961431A1 (en) 1997-12-02 2008-08-27 Hoya Corporation Intraocular lenses and process for producing molded-in type intraocular lenses
FR2772033A1 (fr) 1997-12-05 1999-06-04 Essilor Int Procede de fabrication d'un materiau polymere transparent resistant au depot de proteines, materiau obtenu par ce procede, lentilles de contact et implants intraoculaires faits de ce materiau
ES2201673T3 (es) 1998-02-11 2004-03-16 Rtp Pharma Corporation Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios.
US5998498A (en) 1998-03-02 1999-12-07 Johnson & Johnson Vision Products, Inc. Soft contact lenses
US7052131B2 (en) 2001-09-10 2006-05-30 J&J Vision Care, Inc. Biomedical devices containing internal wetting agents
US6087415A (en) 1998-06-11 2000-07-11 Johnson & Johnson Vision Care, Inc. Biomedical devices with hydrophilic coatings
JP2000010055A (ja) 1998-06-19 2000-01-14 Seed Co Ltd 親水性眼用レンズ及びその製造方法
JP3824791B2 (ja) 1998-10-01 2006-09-20 株式会社ニデック 眼内レンズの製造方法
HUP0104197A3 (en) 1998-10-13 2003-03-28 Pharmacia Groningen Bv Injectable intraocular lens
SE9803481D0 (sv) 1998-10-13 1998-10-13 Pharmacia & Upjohn Ab Photocurable siloxane polymers
US6291519B1 (en) * 1998-10-14 2001-09-18 Novartis Ag Method of preventing damage to eye tissue
CA2348495C (en) 1998-10-29 2008-07-15 Allergan Sales, Inc. Intraocular lenses made from polymeric compositions
US7297214B2 (en) * 1999-09-03 2007-11-20 Kiyohito Ishida Free cutting alloy
CN1387435A (zh) 1999-11-09 2002-12-25 爱尔康公司 用于治疗干眼的脂毒素a4及其衍生物
US6576663B2 (en) 1999-12-22 2003-06-10 Alcon, Inc. 6-Keto prostaglandin F1α and analogs for treating dry eye
JP4434397B2 (ja) * 1999-12-28 2010-03-17 株式会社シード 軟質眼用レンズ
IL134240A0 (en) 2000-01-27 2001-04-30 Senyorina Ltd Inositol derivatives and their pharmaceutical use
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US6531432B2 (en) 2000-12-07 2003-03-11 Johnson & Johnson Vision Care, Inc. Contact lens packaging solutions
DE60227078D1 (de) 2001-05-30 2008-07-24 Yeda Res & Dev Allylmercaptocaptoprilverbindungen und deren verwendungen
CA2469647C (en) * 2001-12-12 2011-02-15 Daniel G. Dueppen Extraction and winterization of lipids from oilseed and microbial sources
ATE382597T1 (de) 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
JPWO2004004738A1 (ja) 2002-07-02 2005-11-04 わかもと製薬株式会社 角結膜上皮細胞障害治療薬又は予防薬
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
AU2003259145A1 (en) 2002-07-17 2004-02-02 Spencer P. Thornton Treatment for dry eye syndrome
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
CA2467410A1 (en) 2003-05-27 2004-11-27 Synphora Ab Method for treatment of glaucoma and ocular hypertension with prostaglandin analgoues without melanogenic side-effect
FR2857770B1 (fr) * 2003-07-18 2005-10-21 Valois Sas Indicateur de doses ameliore pour dispositif de distribution de produit fluide.
US20050103466A1 (en) 2003-11-19 2005-05-19 Landry Kenneth D. Refrigerator-oven
US20050220742A1 (en) 2004-03-31 2005-10-06 Breen Ed V Compositions and methods for maintaining eyelid hygiene
CA2572344A1 (en) * 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US7553860B2 (en) 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20070293410A1 (en) * 2006-06-15 2007-12-20 Surowiak Richard J Contact lens and method for preventing contact lens intolerance
US20100105773A1 (en) 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
GB0623299D0 (en) 2006-11-22 2007-01-03 Sauflon Cl Ltd Contact lens
WO2008070129A2 (en) 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
RU2336851C1 (ru) 2007-06-21 2008-10-27 Эрнест Витальевич Бойко Мягкая контактная линза
US10105441B2 (en) 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
TWI419719B (zh) 2007-08-31 2013-12-21 Novartis Ag 隱形眼鏡產物
JP5421272B2 (ja) 2007-10-12 2014-02-19 リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド 眼病治療のための組成物及び方法
US7884141B2 (en) 2007-11-14 2011-02-08 Bausch & Lomb Incorporated Biomedical devices
CN101903807B (zh) * 2007-12-20 2013-01-09 诺瓦提斯公司 隐形眼镜的制造方法
US20100105772A1 (en) 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
TWI506333B (zh) 2008-12-05 2015-11-01 Novartis Ag 用以傳遞疏水性舒適劑之眼用裝置及其製造方法
NZ595204A (en) 2009-03-09 2014-11-28 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
JP6123860B2 (ja) 2015-09-17 2017-05-10 王子ホールディングス株式会社 ベルト型使い捨ておむつ
JP2017195808A (ja) * 2016-04-27 2017-11-02 三菱ケミカル株式会社 カンゾウ属植物の育成方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170006A2 (en) 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11077084B2 (en) 2012-05-10 2021-08-03 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11077083B2 (en) 2012-05-10 2021-08-03 Solutex Na Llc Oils with anti-inflammatory activity containing natural Specialized Proresolving Mediators and their precursors
US11285126B2 (en) 2012-05-10 2022-03-29 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11865096B2 (en) 2012-05-10 2024-01-09 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US11020406B2 (en) 2015-09-03 2021-06-01 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
US11559529B2 (en) 2015-09-03 2023-01-24 Solutex Na Llc Compositions comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
US11833158B2 (en) 2015-09-03 2023-12-05 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same

Also Published As

Publication number Publication date
RU2707961C2 (ru) 2019-12-03
JP2014518261A (ja) 2014-07-28
RU2017142720A3 (pt) 2019-06-07
ES2743174T3 (es) 2020-02-18
RU2017142720A (ru) 2019-06-07
AU2022228206A1 (en) 2022-10-06
RU2018133283A3 (pt) 2020-03-20
KR20190108648A (ko) 2019-09-24
TWI713867B (zh) 2020-12-21
CA2840155C (en) 2021-09-14
CN108969471A (zh) 2018-12-11
BR112013033941A2 (pt) 2017-02-14
RU2747953C2 (ru) 2021-05-17
KR20140146037A (ko) 2014-12-24
AU2022202729A1 (en) 2022-05-19
RU2640506C9 (ru) 2018-05-11
JP6352177B2 (ja) 2018-07-04
AU2012275759A1 (en) 2014-01-23
EP3556346B1 (en) 2021-10-13
EP2726061B1 (en) 2017-02-22
TW201906596A (zh) 2019-02-16
US20140364400A1 (en) 2014-12-11
TWI587857B (zh) 2017-06-21
AU2020281097A1 (en) 2021-01-07
WO2013003113A1 (en) 2013-01-03
US10588887B2 (en) 2020-03-17
KR102022838B1 (ko) 2019-09-20
CN108272783B (zh) 2020-11-17
AU2019203920A1 (en) 2019-06-20
US20210379005A1 (en) 2021-12-09
CN107260716A (zh) 2017-10-20
CA2840152C (en) 2021-06-08
KR102203310B1 (ko) 2021-01-15
AU2019204333A1 (en) 2019-07-11
JP2019178150A (ja) 2019-10-17
TW201818920A (zh) 2018-06-01
EP2726058B1 (en) 2019-06-19
AU2012275760A1 (en) 2014-01-23
WO2013003114A8 (en) 2013-07-25
RU2673230C1 (ru) 2018-11-23
PL3556346T3 (pl) 2022-01-31
US20200222357A1 (en) 2020-07-16
KR20190108650A (ko) 2019-09-24
CN103796635A (zh) 2014-05-14
KR20140048947A (ko) 2014-04-24
AU2019204333A8 (en) 2019-08-22
CN108272783A (zh) 2018-07-13
RU2018136873A (ru) 2020-04-20
CA2840152A1 (en) 2013-01-03
US20130005691A1 (en) 2013-01-03
US20200206178A1 (en) 2020-07-02
KR102023326B1 (ko) 2019-11-04
AU2017204759A1 (en) 2017-07-27
AU2019203920B2 (en) 2020-05-14
US11096919B2 (en) 2021-08-24
AU2012275760B2 (en) 2017-08-03
RU2019137026A (ru) 2021-05-19
RU2017125922A (ru) 2019-01-31
CN103813783A (zh) 2014-05-21
TW201315465A (zh) 2013-04-16
AU2017204838B2 (en) 2019-03-21
RU2018133283A (ru) 2020-03-20
RU2014102996A (ru) 2015-08-10
TW201315464A (zh) 2013-04-16
AU2020204211A1 (en) 2020-07-16
RU2014102958A (ru) 2015-08-10
US20190328698A1 (en) 2019-10-31
BR112013034054A2 (pt) 2017-02-07
JP6675361B2 (ja) 2020-04-01
US10383839B2 (en) 2019-08-20
RU2627438C2 (ru) 2017-08-08
AU2017204759B2 (en) 2019-03-07
JP2014518262A (ja) 2014-07-28
EP2726061A1 (en) 2014-05-07
EP2726058A1 (en) 2014-05-07
EP3556346A1 (en) 2019-10-23
US20130005805A1 (en) 2013-01-03
AU2017204838A1 (en) 2017-08-03
RU2640506C2 (ru) 2018-01-09
RU2018136873A3 (pt) 2020-04-20
AR086824A1 (es) 2014-01-22
US8865685B2 (en) 2014-10-21
CA2840155A1 (en) 2013-01-03
AU2017204838B9 (en) 2021-09-09
RU2017125922A3 (pt) 2019-01-31
WO2013003114A1 (en) 2013-01-03
US11311510B2 (en) 2022-04-26
JP2018065792A (ja) 2018-04-26
TWI633883B (zh) 2018-09-01
AR086825A1 (es) 2014-01-22

Similar Documents

Publication Publication Date Title
JP6675361B2 (ja) 眼の炎症状態を治療するためのエステル

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180124

R150 Certificate of patent or registration of utility model

Ref document number: 6282586

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees